Review



biotinylated antibody against ifn β  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems biotinylated antibody against ifn β
    Biotinylated Antibody Against Ifn β, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 130 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+mouse+ifn/Mouse+IFN-beta+DuoSet+ELISA/pm41708603-458-21-34
    Average 96 stars, based on 130 article reviews
    biotinylated antibody against ifn β - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: MERS-CoV vaccine
    Article Snippet: Peptide pools consisted of 15-mer peptides overlapping by 11 amino acids (GenScript). .. After 24 h of stimulation, the cells were washed and incubated for 24 h at 4° C. with biotinylated anti-mouse IFN-γ Abs (R&D Systems). .. The plates were washed, and streptavidin-alkaline phosphatase (R&D Systems) was added to each well and incubated for 2 h at room temperature.

    Article Title: MERS-CoV vaccine
    Article Snippet: Peptide pools consisted of 15-mer peptides overlapping by 11 amino acids (GenScript). .. After 24 h of stimulation, the cells were washed and incubated for 24 h at 4° C. with biotinylated anti-mouse IFN-γ Abs (R&D Systems). .. The plates were washed, and streptavidin-alkaline phosphatase (R&D Systems) was added to each well and incubated for 2 h at room temperature.

    Article Title: Vaccines with biomolecular adjuvants
    Article Snippet: CD4+ or CD8+ T cells (5×105 cells/well plated in triplicate) were MACS-purified (Miltenyibiotec, San Diego, Calif., USA) from splenocytes and subsequently stimulated with HIV-1 Gag (consensus subtype B) or Env (subtype B (MN)) peptides (15-mers overlapping by 11 amino acids, spanning the lengths of their respective protein (NIH AIDS Reagent Program, Bethesda, Md., USA). .. After 18-24 h of stimulation overnight at 37° C. in 5% CO2, the plates were washed in PBS and subsequently incubated for an additional 24 h at 4° C. with biotinylated anti-mouse IFN-γ monoclonal antibody (mAb) purchased from R&D Systems (Minneapolis, Minn., USA). .. The plates were then washed again in PBS, and streptavidin-alkaline phosphatase (MabTech, Nacka Strand, Sweden) was added to each well and incubated for 2 h at RT.

    Article Title: MERS-CoV vaccine
    Article Snippet: Peptide pools consisted of 15-mer peptides overlapping by 11 amino acids (GenScript). .. After 24 h of stimulation, the cells were washed and incubated for 24 h at 4° C. with biotinylated anti-mouse IFN-γ Abs (R&D Systems). .. The plates were washed, and streptavidin-alkaline phosphatase (R&D Systems) was added to each well and incubated for 2 h at room temperature.

    Article Title: Vaccines with biomolecular adjuvants
    Article Snippet: CD4+ or CD8+ T cells (5×105 cells/well plated in triplicate) were MACS-purified (Miltenyibiotec, San Diego, Calif., USA) from splenocytes and subsequently stimulated with HIV-1 Gag (consensus subtype B) or Env (subtype B (MN)) peptides (15-mers overlapping by 11 amino acids, spanning the lengths of their respective protein (NIH AIDS Reagent Program, Bethesda, Md., USA). .. After 18-24 h of stimulation overnight at 37° C. in 5% CO2, the plates were washed in PBS and subsequently incubated for an additional 24 h at 4° C. with biotinylated anti-mouse IFN-γ monoclonal antibody (mAb) purchased from R&D Systems (Minneapolis, Minn., USA). .. The plates were then washed again in PBS, and streptavidin-alkaline phosphatase (MabTech, Nacka Strand, Sweden) was added to each well and incubated for 2 h at RT.

    Article Title: A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
    Article Snippet: Peptide pools consisted of 15-mer peptides overlapping by 11 amino acids and spanned the entire S protein (GenScript). .. After 24 hours of stimulation, the plates were washed and incubated for 24 hours at 4°C with biotinylated anti-mouse IFN-γ antibodies (R&D Systems). .. The plates were washed, streptavidin-alkaline phosphatase (R&D Systems) was added to each well, and the plates were incubated for 2 hours at room temperature.

    Article Title: MERS-CoV vaccine
    Article Snippet: Peptide pools consisted of 15-mer peptides overlapping by 11 amino acids (GenScript). .. After 24 h of stimulation, the cells were washed and incubated for 24 h at 4° C. with biotinylated anti-mouse IFN-γ Abs (R&D Systems). .. The plates were washed, and streptavidin-alkaline phosphatase (R&D Systems) was added to each well and incubated for 2 h at room temperature.



    Similar Products

    86
    Mabtech Inc biotinylated anti mouse ifn γ detection antibody
    Biotinylated Anti Mouse Ifn γ Detection Antibody, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+mouse+ifn/anti+biotinylated+detection+ifn+mouse+%CE%B3/bio_rxiv__64898__2026__05__13__723724-228-6-12
    Average 86 stars, based on 1 article reviews
    biotinylated anti mouse ifn γ detection antibody - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Mabtech Inc biotinylated anti mouse ifn
    CVB1 vaccines formulated with adjuvant system 04 (AS04, containing MPLA and Alhydrogel) elicit strong immune response in mice. a Schematic of the immunization protocol. Female C57BL/6J mice (n = 9 per group) were immunized subcutaneously with a 2 µg dose of CVB1 vaccines formulated with AS04 at weeks 0 and 3. b Average body weight of animals in each group during the study period. The dashed line indicates the time of booster vaccination. c CVB1-neutralizing antibody (nAb) endpoint titers determined from terminal serum using a microneutralization assay. Titers above 8 were considered positive (horizontal line). d Vaccine antigen-specific IgG, e IgG1, and f IgG2a endpoint titers determined by indirect ELISA. Titers above 200 were considered positive (horizontal line). g VP4-specific antibody endpoint titers determined by indirect ELISA. Titers above 100 were considered positive (horizontal line). Antibody end-point titers are presented as scatter dot plots showing individual mice, geometric mean titers, and 95% confidence intervals. h Antibody-mediated infection assay. IFN-α concentrations in culture supernatants of primary spleen cells inoculated with CVB1 mixed with diluted serum from vaccinated or control mice, measured by ELISA. IFN-α concentrations of individual mice are shown as scatter dot plots with mean concentration and 95% confidence intervals. <t>i</t> <t>IFN-γ</t> secreting splenocytes following vaccine antigen stimulation and i VP4 stimulation determined with ELISpot assay. The amount of IFN-γ secreting cells on individual mice are shown as scatter dot plots with mean and 95% confidence intervals. Statistical significances were determined by Kruskal-Wallis test with Dunn’s post hoc comparison. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Biotinylated Anti Mouse Ifn, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+mouse+ifn/anti+ifn+%CE%B3/pmc13019872-177-7-12
    Average 86 stars, based on 1 article reviews
    biotinylated anti mouse ifn - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    96
    R&D Systems biotinylated antibody against ifn β
    CVB1 vaccines formulated with adjuvant system 04 (AS04, containing MPLA and Alhydrogel) elicit strong immune response in mice. a Schematic of the immunization protocol. Female C57BL/6J mice (n = 9 per group) were immunized subcutaneously with a 2 µg dose of CVB1 vaccines formulated with AS04 at weeks 0 and 3. b Average body weight of animals in each group during the study period. The dashed line indicates the time of booster vaccination. c CVB1-neutralizing antibody (nAb) endpoint titers determined from terminal serum using a microneutralization assay. Titers above 8 were considered positive (horizontal line). d Vaccine antigen-specific IgG, e IgG1, and f IgG2a endpoint titers determined by indirect ELISA. Titers above 200 were considered positive (horizontal line). g VP4-specific antibody endpoint titers determined by indirect ELISA. Titers above 100 were considered positive (horizontal line). Antibody end-point titers are presented as scatter dot plots showing individual mice, geometric mean titers, and 95% confidence intervals. h Antibody-mediated infection assay. IFN-α concentrations in culture supernatants of primary spleen cells inoculated with CVB1 mixed with diluted serum from vaccinated or control mice, measured by ELISA. IFN-α concentrations of individual mice are shown as scatter dot plots with mean concentration and 95% confidence intervals. <t>i</t> <t>IFN-γ</t> secreting splenocytes following vaccine antigen stimulation and i VP4 stimulation determined with ELISpot assay. The amount of IFN-γ secreting cells on individual mice are shown as scatter dot plots with mean and 95% confidence intervals. Statistical significances were determined by Kruskal-Wallis test with Dunn’s post hoc comparison. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Biotinylated Antibody Against Ifn β, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+mouse+ifn/Mouse+IFN-beta+DuoSet+ELISA/pm41708603-458-21-34
    Average 96 stars, based on 1 article reviews
    biotinylated antibody against ifn β - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    86
    Mabtech Inc biotinylated rat anti mouse ifn
    CVB1 vaccines formulated with adjuvant system 04 (AS04, containing MPLA and Alhydrogel) elicit strong immune response in mice. a Schematic of the immunization protocol. Female C57BL/6J mice (n = 9 per group) were immunized subcutaneously with a 2 µg dose of CVB1 vaccines formulated with AS04 at weeks 0 and 3. b Average body weight of animals in each group during the study period. The dashed line indicates the time of booster vaccination. c CVB1-neutralizing antibody (nAb) endpoint titers determined from terminal serum using a microneutralization assay. Titers above 8 were considered positive (horizontal line). d Vaccine antigen-specific IgG, e IgG1, and f IgG2a endpoint titers determined by indirect ELISA. Titers above 200 were considered positive (horizontal line). g VP4-specific antibody endpoint titers determined by indirect ELISA. Titers above 100 were considered positive (horizontal line). Antibody end-point titers are presented as scatter dot plots showing individual mice, geometric mean titers, and 95% confidence intervals. h Antibody-mediated infection assay. IFN-α concentrations in culture supernatants of primary spleen cells inoculated with CVB1 mixed with diluted serum from vaccinated or control mice, measured by ELISA. IFN-α concentrations of individual mice are shown as scatter dot plots with mean concentration and 95% confidence intervals. <t>i</t> <t>IFN-γ</t> secreting splenocytes following vaccine antigen stimulation and i VP4 stimulation determined with ELISpot assay. The amount of IFN-γ secreting cells on individual mice are shown as scatter dot plots with mean and 95% confidence intervals. Statistical significances were determined by Kruskal-Wallis test with Dunn’s post hoc comparison. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Biotinylated Rat Anti Mouse Ifn, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+mouse+ifn/9g4+anti+rat/us12544415-781-0-6
    Average 86 stars, based on 1 article reviews
    biotinylated rat anti mouse ifn - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    96
    R&D Systems biotinylated secondary antibody
    CVB1 vaccines formulated with adjuvant system 04 (AS04, containing MPLA and Alhydrogel) elicit strong immune response in mice. a Schematic of the immunization protocol. Female C57BL/6J mice (n = 9 per group) were immunized subcutaneously with a 2 µg dose of CVB1 vaccines formulated with AS04 at weeks 0 and 3. b Average body weight of animals in each group during the study period. The dashed line indicates the time of booster vaccination. c CVB1-neutralizing antibody (nAb) endpoint titers determined from terminal serum using a microneutralization assay. Titers above 8 were considered positive (horizontal line). d Vaccine antigen-specific IgG, e IgG1, and f IgG2a endpoint titers determined by indirect ELISA. Titers above 200 were considered positive (horizontal line). g VP4-specific antibody endpoint titers determined by indirect ELISA. Titers above 100 were considered positive (horizontal line). Antibody end-point titers are presented as scatter dot plots showing individual mice, geometric mean titers, and 95% confidence intervals. h Antibody-mediated infection assay. IFN-α concentrations in culture supernatants of primary spleen cells inoculated with CVB1 mixed with diluted serum from vaccinated or control mice, measured by ELISA. IFN-α concentrations of individual mice are shown as scatter dot plots with mean concentration and 95% confidence intervals. <t>i</t> <t>IFN-γ</t> secreting splenocytes following vaccine antigen stimulation and i VP4 stimulation determined with ELISpot assay. The amount of IFN-γ secreting cells on individual mice are shown as scatter dot plots with mean and 95% confidence intervals. Statistical significances were determined by Kruskal-Wallis test with Dunn’s post hoc comparison. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Biotinylated Secondary Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+mouse+ifn/Mouse+IFN-gamma+ELISpot+Kit/10__3390_slash_vaccines14020114-86-8-13
    Average 96 stars, based on 1 article reviews
    biotinylated secondary antibody - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    86
    Mabtech Inc biotinylated anti mouse ifn γ antibody r4 6a2 biotin
    CVB1 vaccines formulated with adjuvant system 04 (AS04, containing MPLA and Alhydrogel) elicit strong immune response in mice. a Schematic of the immunization protocol. Female C57BL/6J mice (n = 9 per group) were immunized subcutaneously with a 2 µg dose of CVB1 vaccines formulated with AS04 at weeks 0 and 3. b Average body weight of animals in each group during the study period. The dashed line indicates the time of booster vaccination. c CVB1-neutralizing antibody (nAb) endpoint titers determined from terminal serum using a microneutralization assay. Titers above 8 were considered positive (horizontal line). d Vaccine antigen-specific IgG, e IgG1, and f IgG2a endpoint titers determined by indirect ELISA. Titers above 200 were considered positive (horizontal line). g VP4-specific antibody endpoint titers determined by indirect ELISA. Titers above 100 were considered positive (horizontal line). Antibody end-point titers are presented as scatter dot plots showing individual mice, geometric mean titers, and 95% confidence intervals. h Antibody-mediated infection assay. IFN-α concentrations in culture supernatants of primary spleen cells inoculated with CVB1 mixed with diluted serum from vaccinated or control mice, measured by ELISA. IFN-α concentrations of individual mice are shown as scatter dot plots with mean concentration and 95% confidence intervals. <t>i</t> <t>IFN-γ</t> secreting splenocytes following vaccine antigen stimulation and i VP4 stimulation determined with ELISpot assay. The amount of IFN-γ secreting cells on individual mice are shown as scatter dot plots with mean and 95% confidence intervals. Statistical significances were determined by Kruskal-Wallis test with Dunn’s post hoc comparison. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Biotinylated Anti Mouse Ifn γ Antibody R4 6a2 Biotin, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+mouse+ifn/anti+biotinylated+detection+ferret+ifn+%CE%B3/us12514888-267-17-22
    Average 86 stars, based on 1 article reviews
    biotinylated anti mouse ifn γ antibody r4 6a2 biotin - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    Image Search Results


    CVB1 vaccines formulated with adjuvant system 04 (AS04, containing MPLA and Alhydrogel) elicit strong immune response in mice. a Schematic of the immunization protocol. Female C57BL/6J mice (n = 9 per group) were immunized subcutaneously with a 2 µg dose of CVB1 vaccines formulated with AS04 at weeks 0 and 3. b Average body weight of animals in each group during the study period. The dashed line indicates the time of booster vaccination. c CVB1-neutralizing antibody (nAb) endpoint titers determined from terminal serum using a microneutralization assay. Titers above 8 were considered positive (horizontal line). d Vaccine antigen-specific IgG, e IgG1, and f IgG2a endpoint titers determined by indirect ELISA. Titers above 200 were considered positive (horizontal line). g VP4-specific antibody endpoint titers determined by indirect ELISA. Titers above 100 were considered positive (horizontal line). Antibody end-point titers are presented as scatter dot plots showing individual mice, geometric mean titers, and 95% confidence intervals. h Antibody-mediated infection assay. IFN-α concentrations in culture supernatants of primary spleen cells inoculated with CVB1 mixed with diluted serum from vaccinated or control mice, measured by ELISA. IFN-α concentrations of individual mice are shown as scatter dot plots with mean concentration and 95% confidence intervals. i IFN-γ secreting splenocytes following vaccine antigen stimulation and i VP4 stimulation determined with ELISpot assay. The amount of IFN-γ secreting cells on individual mice are shown as scatter dot plots with mean and 95% confidence intervals. Statistical significances were determined by Kruskal-Wallis test with Dunn’s post hoc comparison. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Journal: Journal of Biomedical Science

    Article Title: Coxsackie B1 virus-like particle that lacks VP4 protein demonstrates improved vaccine scalability, stability and immunogenicity

    doi: 10.1186/s12929-026-01229-y

    Figure Lengend Snippet: CVB1 vaccines formulated with adjuvant system 04 (AS04, containing MPLA and Alhydrogel) elicit strong immune response in mice. a Schematic of the immunization protocol. Female C57BL/6J mice (n = 9 per group) were immunized subcutaneously with a 2 µg dose of CVB1 vaccines formulated with AS04 at weeks 0 and 3. b Average body weight of animals in each group during the study period. The dashed line indicates the time of booster vaccination. c CVB1-neutralizing antibody (nAb) endpoint titers determined from terminal serum using a microneutralization assay. Titers above 8 were considered positive (horizontal line). d Vaccine antigen-specific IgG, e IgG1, and f IgG2a endpoint titers determined by indirect ELISA. Titers above 200 were considered positive (horizontal line). g VP4-specific antibody endpoint titers determined by indirect ELISA. Titers above 100 were considered positive (horizontal line). Antibody end-point titers are presented as scatter dot plots showing individual mice, geometric mean titers, and 95% confidence intervals. h Antibody-mediated infection assay. IFN-α concentrations in culture supernatants of primary spleen cells inoculated with CVB1 mixed with diluted serum from vaccinated or control mice, measured by ELISA. IFN-α concentrations of individual mice are shown as scatter dot plots with mean concentration and 95% confidence intervals. i IFN-γ secreting splenocytes following vaccine antigen stimulation and i VP4 stimulation determined with ELISpot assay. The amount of IFN-γ secreting cells on individual mice are shown as scatter dot plots with mean and 95% confidence intervals. Statistical significances were determined by Kruskal-Wallis test with Dunn’s post hoc comparison. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Article Snippet: Detection was performed using 0.2 μg/well of biotinylated anti-mouse IFN-γ monoclonal antibody (Mabtech) for 2 h at room temperature (RT), followed by streptavidin-ALP (1:500 dilution, Mabtech) for 1 h at RT, and finally BCIP/NBT-plus substrate (Mabtech) for 10 min of color development.

    Techniques: Vaccines, Adjuvant, Microneutralization Assay, Indirect ELISA, Infection, Control, Enzyme-linked Immunosorbent Assay, Concentration Assay, Enzyme-linked Immunospot, Comparison